Weight & Metabolism Research Peptides
Compare Retatrutide, Tirzepatide, MOTS-c and Tesamorelin. See how receptor studies, clinical weight outcomes, cellular-energy experiments and imaging measurements answer different questions.
Compare the listings4 products
Compare four materials and their research pathways
Metabolism is a broad subject. It includes how cells process nutrients, how receptors participate in signalling and how whole-body outcomes are measured in research. Everyday language such as energy or weight management may help you find a starting point, but it does not describe one single mechanism.
Retatrutide, tirzepatide, MOTS-c and tesamorelin should not be read as interchangeable entries in a ranked list. They are discussed through different pathways and bodies of evidence. Compare the exact research question first, then the study design and material. Package price and nominal milligrams belong in a separate comparison of the current listings.
NAD+ may also appear in cellular-metabolism discussions. It is a coenzyme, not a peptide. Keeping that distinction visible helps make this category a useful research map rather than a collection of similar-sounding claims.
| Compound | Research context | Important comparison check |
|---|---|---|
| Retatrutide | GLP-1, GIP and glucagon receptor signalling | Read the formulation, population, endpoints and limitations of the specific study. |
| Tirzepatide | GIP and GLP-1 receptor signalling | Distinguish pathway differences from an untested comparison of outcomes. |
| MOTS-c | Mitochondrial-derived peptide and metabolic models | Distinguish cellular or animal findings from established everyday energy outcomes. |
| Tesamorelin | Growth-hormone-releasing hormone signalling | Separate visceral-fat endpoints in defined study populations from general weight claims. |
| NAD+ | Cellular redox and coenzyme research | Do not treat evidence on precursors or other forms as automatically applying to a supplied NAD+ vial. |
| Semaglutide, when discussed in comparisons | GLP-1 receptor signalling | Keep the educational comparison even if no purchase option is currently offered. |
What incretin and glucagon receptor research explains
GLP-1, GIP and glucagon are names you will encounter in incretin-related research. Retatrutide has been investigated as a three-receptor agonist; tirzepatide is discussed through GIP and GLP-1 receptor activity. Those descriptions identify research pathways. They do not make the current catalogue materials equivalent to the formulations investigated in a trial.
The retatrutide phase 2 paper is one example of a defined clinical study with a specified population, comparator and duration. Read it as that particular study, rather than treating a headline result as a result for every population or for a research vial. Separate study results should not be presented as a head-to-head trial when no such comparison was performed.
Mitochondrial research asks different questions
MOTS-c belongs to the discussion of mitochondrial-derived peptides and metabolic signalling. Foundational work included cellular and mouse experiments. That research context is distinct from a clinical trial measuring a change in body weight and from a claim about how energetic someone feels.
When reading MOTS-c research, look for the model, the material and the actual measurement. A cellular pathway and a whole-person outcome are different levels of evidence. The mitochondrial-peptide guide introduces the terminology, while the compound profile connects the name to its research background.
Why Tesamorelin belongs in a separate comparison
Tesamorelin is discussed in growth-hormone signalling research. A visceral-fat endpoint is different from total body weight, and the characteristics of the study population matter. Its inclusion in a metabolism category is a browsing aid, not a statement that it addresses the same question as an incretin-related compound or MOTS-c.
Use the MOTS-c vs tesamorelin guide to see the pathway and evidence distinctions before opening the product listings. The Growth Hormone category provides a second route when signalling mechanisms are your main interest.
Keep evidence and product information separate
For a paper, check population or model, intervention material, comparator, measurement and limitations. For a supplied material, check identity, form, size and available batch records. These two checklists work together without replacing one another. Current catalogue availability is not a conclusion about the research, and a published study is not a certificate for the vial.
| Question | Source to look for | Check first |
|---|---|---|
| How did body weight change? | Controlled human trial. | Population, time point and analysis. |
| How did cells respond? | Cell or animal experiment. | Model, assay and comparison group. |
| Did visceral fat change? | Imaging study in the relevant population. | Compartment and measurement method. |
Keep cellular-energy discovery visible
Retatrutide and Tirzepatide belong to receptor-signalling discussions, while MOTS-c introduces mitochondrial and cellular-energy research. A shared browsing area does not imply the same mechanism, evidence base or measured outcome.
These collections organise research interests; they are not personal treatment recommendations or promises of an outcome. Peptide Blends is a product format.
A closer look at weight & metabolism research
Metabolism is broader than body weight
Metabolism describes the processes involved in using, storing and regulating energy. Weight management is one research interest within that broader subject. Body weight, appetite, glucose regulation, insulin sensitivity, energy expenditure and visceral fat are distinct endpoints. Retatrutide, MOTS-c and tesamorelin appear in related searches, but they are not three versions of one compound. A useful first step is to identify which pathway and endpoint each study addresses, rather than ranking names from their category label or vial size.
Three research routes to compare
Retatrutide is studied as an agonist at GLP-1, GIP and glucagon receptors. MOTS-c is a mitochondrial-derived peptide with a different experimental background. Tesamorelin is a growth hormone-releasing hormone analogue, and its body-composition research includes specific clinical populations. These mechanisms explain why a search for metabolic peptides can return different families of material. They do not establish equivalent effects. The comparison guides separate the receptor-targeting compounds from the mitochondrial and growth-hormone conversations so you can read each line of evidence in its own context.
Interpreting a weight-management study
Check who participated, what was compared, how long the study ran and how missing observations were handled. A percentage change in body weight is not the same outcome as a change in visceral adipose tissue or an insulin-related laboratory measure. Cross-trial percentages should not be presented as a head-to-head contest when the populations and designs differ. The Retatrutide profile and the three-way receptor comparison point to the source research. Product tables answer a separate question: which package options and current CAD prices are actually listed in this catalogue.
A practical reading order is to identify the compound, compare a related listing, then read the underlying study and the product documentation. The Research Library explains the terminology. Use the COA checklist to distinguish sample identity, analytical purity and measured content. The evidence-reading guide explains how to keep a laboratory observation separate from a result measured in people.
Weight & Metabolism questions
Are all compounds in this category incretin peptides?
No. The category spans several research contexts, including mitochondrial-derived peptide and growth-hormone signalling research. NAD+ is a coenzyme rather than a peptide.
Does a larger vial amount identify a more effective compound?
No. Nominal mass is a package specification, not a cross-compound measure of effectiveness. Compare amounts within the same defined material and specification.
Is a clinical-trial formulation interchangeable with a catalogue vial?
No equivalence should be assumed. The trial material, formulation and controls need to be considered separately from the supplied research listing.
Why keep an unavailable compound in a comparison?
Its educational differences still matter. Current stock and purchase controls can change without removing the reference information.
Is cellular-energy research the same as a proven increase in everyday energy?
No. Read the specific measurement and study model. A pathway observation should not be substituted for an outcome that was not measured.
How do I compare a weight trial with a visceral-fat study?
Keep the outcome and population beside each result. Overall body weight and imaging of a specific fat compartment are separate endpoints.
Follow the research
Sources and study context
PRIMARY SOURCES: Lee et al., Cell Metabolism (2015), PMID 25738459, Read the original study; Jastreboff et al., NEJM (2023), PMID 37366315, Read the original study; Falutz et al., NEJM (2007), PMID 18057338, Read the original study.




